List of investigational analgesics
This is a list of investigational analgesics, or analgesics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.- Axelopran/oxycodone – combination of a centrally active μ-opioid receptor agonist and a peripherally selective μ-, κ-, and δ-opioid receptor antagonist
- Cebranopadol – non-selective μ-opioid receptor, nociceptin receptor, and δ-opioid receptor full agonist and κ-opioid receptor partial agonist
- Desmetramadol – μ-opioid receptor agonist, norepinephrine reuptake inhibitor, and 5-HT2C receptor antagonist
- Difelikefalin – peripherally selective κ-opioid receptor agonist
- Lexanopadol – non-selective opioid receptor agonist
- NKTR-181 – selective μ-opioid receptor full agonist that slowly enters the brain
- Oliceridine – μ-opioid receptor biased agonist
- Oxycodone/naltrexone – combination of a μ-opioid receptor agonist and a μ- and κ-opioid receptor antagonist
- CC-8464 – selective Nav1.7 blocker
- Cenobamate – atypical voltage-gated sodium channel blocker
- DSP-2230 – selective Nav1.7 and Nav1.8 blocker
- Funapide – selective Nav1.7 and Nav1.8 blocker
- GDC-0276 – selective Nav1.7 blocker
- GDC-0310 – selective Nav1.7 blocker
- NKTR-171 – voltage-gated sodium channel blocker
- PF-05089771 – selective Nav1.7 and Nav1.8 blocker
- Ralfinamide – non-selective voltage-gated sodium channel blocker, as well as other actions
- Tetrodotoxin – non-selective voltage-gated sodium channel blocker
- Vixotrigine – non-selective voltage-gated sodium channel blocker
- VX-150 – selective Nav1.8 blocker
channel modulators
- Capsaicin – TRPV1 agonist
- Capsaicin/diclofenac – combination of a TRPV1 agonist and a COX-2 inhibitor for topical application
- CMX-020 – TRPV1 modulator as well as CB1 and CB2 receptor modulator
- DWP-05195 – TRPV1 antagonist
- GRC-6211 – TRPV1 agonist
- JNJ-38893777 – TRPV1 antagonist
- Mavatrep – TRPV1 antagonist
- NEO-6860 – TRPV1 antagonist
- Parentide – TRPV1 antagonist
- Resiniferatoxin – TRPV1 agonist
- SAR-115740 – TRPV1 antagonist
- Tivanisiran – TRPV1 antagonist
- ABX-1431 – selective monoacylglycerol lipase inhibitor
- Cannabidiol – cannabinoid receptor modulator
- Cannabidivarin – cannabinoid receptor modulator
- CMX-020 – TRPV1 modulator as well as CB1 and CB2 receptor modulator
- Dronabinol – CB1 and CB2 receptor agonist
- Nabilone – CB1 and CB2 receptor agonist
- NEO-1940 – CB1 and CB2 receptor agonist
- Olorinab – CB2 receptor agonist
- Fasinumab – monoclonal antibody against nerve growth factor
- Frunevetmab – monoclonal antibody against nerve growth factor for cats
- Fulranumab – monoclonal antibody against nerve growth factor
- GBR-900 – monoclonal antibody against TrkA
- GZ-389988 – TrkA, TrkB, and TrkC kinase inhibitor
- LEVI-04 – LNGF receptor fusion protein and decoy receptor for nerve growth factor
- NRD135S-E1 – tyrosine kinase modulator
- ONO-4474 – peripherally selective TrkA, TrkB, and TrkC kinase inhibitor
- Ranevetmab – monoclonal antibody against nerve growth factor for dogs
- Tanezumab – monoclonal antibody against nerve growth factor
- VM-902A – selective, peripherally selective allosteric inhibitor of TrkA
Others
- ALLOD-2 – undefined mechanism of action
- CR-4056 – imidazoline I2 receptor agonist
- E-52862 – sigma-1 receptor antagonist
- HSP-3150 – undefined mechanism of action
- PAX-01 – undefined mechanism of action
